Biosensors and Bioelectronics Submission Guide

Source: Biosensors and Bioelectronics on ScienceDirect, accessed May 27, 2026.

Source: Biosensors and Bioelectronics Guide for Authors.

Use this page when deciding:

• whether the sensing performance is competitive

• whether real-sample validation is included

• whether biological applicability is direct

• a clear sensing-performance advance (LOD, sensitivity, selectivity)

• real-sample validation in biological matrices

• direct biological applicability

• benchmarking against state-of-the-art biosensors

• a cover letter establishing performance and applicability

• Incremental sensing performance without novel principle.

• Missing real-sample validation.

• Weak biological applicability.

• Missing benchmarking against state-of-the-art.

Biosensors and Bioelectronics is a flagship biosensing journal.

Performance + applicability standard: the journal differentiates from Sensors and Actuators B (broader sensing) and Analytical Chemistry (broader analytical) by demanding both sensing-performance advance and biological applicability.

Real-sample expectation: editors expect validation in biological matrices, not just buffer.

Early editorial screen: buffer-only proof-of-concept work needs stronger real-sample and benchmarking evidence before it belongs in this target.

The strongest Biosensors and Bioelectronics editor-facing notes establish:

• the sensing-performance advance

• the real-sample validation

• the biological applicability

• the benchmarking approach

Method note: the comparison reflects published author guidelines and Manusights internal analysis. We have not personally been Biosensors and Bioelectronics authors; the boundary is publicly documented editorial behavior. Pros and cons are based on documented editorial scope.

For Biosensors and Bioelectronics submissions, the editorial timeline runs through four phases. The journal weights real-sample validation heavily, and the timeline reflects how that filter operates from intake to acceptance.

Day 0 to 5: Editorial Manager intake and editor assignment

Elsevier intake handles format compliance plus the disclosure check. The handling Editor assignment lands within 5 days; biosensor papers route to subject editors with matching transduction-modality expertise (optical, electrochemical, piezoelectric). The most common Day 0-5 hold-up: cover letters that do not explicitly state the real-sample validation context.

Day 5 to 21: Editor scope screen

B&B editors apply a strict performance-quantification filter: selectivity, dynamic range, real-sample matrices, reproducibility across independently fabricated devices. The most common Day 5-21 desk reject in our review work: proof-of-concept sensor papers tested only in buffer or controlled lab solutions without real-sample validation data.

Week 3 to 10: Peer review

Standard 3-4 reviewers, 6-8 week first decision target. Reviewer mix typically includes one sensor-transduction expert plus one application-domain specialist. Submissions missing comparable performance benchmarks against literature or independent-device reproducibility data extend reviewer dialogue by 3-6 weeks.

Week 10 to 24: Decision, revision, and APC

Major revision is the standard first decision at B&B. Revision rounds typically settle at 2 (rarely 3 for accepted papers). Total submission-to-acceptance: 5-8 months for accepted papers. Hybrid open-access option available with APC at acceptance.

• Is Biosensors and Bioelectronics a good journal?

• Biosensors and Bioelectronics overview

• Analytical Chemistry Submission Guide

• Best Analytical Chemistry Journals

• Acta Biomaterialia Submission Guide for biomaterial-device papers whose strongest claim is biological material function rather than sensing performance.

Before upload, run your manuscript through a Biosensors and Bioelectronics performance and applicability readiness check.

Across biosensing manuscripts targeting Biosensors and Bioelectronics, three patterns generate the most consistent desk-screen risk.

Buffer-only performance evidence

For manuscripts targeting Biosensors and Bioelectronics, the first recurring risk is a sensor with strong analytical metrics but weak biological validation. The Guide for Authors defines full papers as complete investigations and the ScienceDirect scope frames the journal around research, design, development, and application of biosensors and bioelectronics. A manuscript can report an impressive LOD, sensitivity, selectivity, response time, or linear range and still feel incomplete if performance is shown only in buffer, pure target solution, or idealized laboratory media.

The repair is to make real-sample validation part of the main claim. The abstract should name the target, matrix, transduction mode, comparator, sample type, and application. The methods should describe sample collection or sourcing, matrix preparation, controls, calibration, interference testing, device-to-device reproducibility, storage stability, and statistical analysis. Figures should include real-sample performance, recovery, clinical or biological comparator where available, and benchmarking against state-of-the-art biosensors for the same target.

The supplementary material should hold extended characterization, not the only real-sample evidence. If the strongest contribution is analytical chemistry without biological material integration, Analytical Chemistry, Sensors and Actuators B, ACS Sensors, Talanta, or a transducer-specific journal may be a better route.

Check whether your Biosensors and Bioelectronics real-sample evidence is strong enough →

Benchmark table without comparable systems

Across Biosensors and Bioelectronics-targeted manuscripts, the second recurring risk is a benchmarking table that looks quantitative but does not compare against comparable systems. Authors often list LOD, dynamic range, response time, or sample type from loosely related sensors, then claim superiority without matching target, matrix, transduction principle, fabrication complexity, or use case. Editors and reviewers can see when the comparison is built to flatter the new sensor rather than test the contribution.

The repair is to build a fair benchmark. The main table should compare sensors for the same or closely related target, in similar sample matrices, with the same practical use case where possible. It should include LOD, sensitivity, dynamic range, selectivity, response time, sample preparation, fabrication reproducibility, number of independent devices, and real-sample validation.

The references should include recent Biosensors and Bioelectronics papers as well as ACS Sensors, Analytical Chemistry, Sensors and Actuators B, and Biosensors and Bioelectronics: X where relevant. The cover letter should explain the performance advance without overclaiming novelty. If the sensor improves one metric while losing on reproducibility, complexity, or real-sample readiness, the manuscript should say so before reviewers do.

Check whether your Biosensors and Bioelectronics benchmarking is fair enough →

Bioelectronics application overclaim

For manuscripts targeting Biosensors and Bioelectronics, the third recurring risk is an application claim that outruns the experiment. Biosensors and bioelectronics papers often point toward diagnostics, wearables, implantables, lab-on-chip systems, DNA chips, electronic noses, or point-of-care workflows. Those claims need evidence about biological material, sample handling, device reproducibility, interference, user context, and practical constraints. A proof-of-concept device can belong in the journal, but only if the manuscript is honest about what has been demonstrated.

The repair is proportional application framing. The abstract should separate demonstrated performance from future use. The methods should specify biological materials, ethics and consent where applicable, sample handling, device fabrication, calibration, and validation. The figures should show stability, reproducibility, selectivity, and matrix effects in the main manuscript. The discussion should distinguish analytical readiness, biological relevance, and clinical or field-readiness.

If the work is mainly circuit design, bioelectronic materials, microfluidic fabrication, or chemical sensing without a biological application test, IEEE biomedical engineering journals, Lab on a Chip, Sensors and Actuators B, ACS Sensors, or a materials venue may fit better.

Check whether your Biosensors and Bioelectronics application claim is proportional →

Check whether your Biosensors and Bioelectronics manuscript is submission-ready →

Clarivate JCR 2024 bibliometric data places Biosensors and Bioelectronics among top biosensing journals.

In pre-submission diagnostic work for top biosensing journals, we consistently see four signals that distinguish strong submissions from weak ones. First, sensing performance metrics (LOD, sensitivity, selectivity, response time) must be clearly reported with appropriate statistical analysis. Second, real-sample validation in biological matrices is expected for biosensors framed for practical diagnostic use. Third, benchmarking against state-of-the-art biosensors for the same target should be explicit and quantitative. Fourth, the biological applicability should be primary; pure analytical chemistry studies fit specialty venues better.

For Biosensors And Bioelectronics-targeted manuscripts, the single most consistent feedback class we deliver in pre-submission diagnostics for Biosensors and Bioelectronics is the buffer-versus-real-sample distinction. Biosensors and Bioelectronics editors expect validation in biological matrices on biosensors framed for diagnostic or biomedical use. Submissions reporting only buffer-based performance routinely receive "where is the real-sample validation?" feedback during desk screening.

We coach authors to include real-sample validation as central evidence, not as an afterthought. Papers framed as "we developed biosensor X with LOD Y in buffer and validated performance in clinical samples Z, demonstrating diagnostic utility against gold-standard W" receive better editorial traction.

The same logic applies across biosensing journals: editors are operating with limited slot inventory, and the submissions that get traction lead with the real-sample evidence.

For Biosensors And Bioelectronics-targeted manuscripts, beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for Biosensors and Bioelectronics. First, manuscripts where the abstract reports buffer-based performance without real-sample data are flagged at desk for applicability framing. We recommend the abstract's central sentences include both sensing performance and real-sample validation.

Second, manuscripts where benchmarking is reported as "compared to literature" without specific named comparison systems are flagged for benchmarking gaps. We recommend explicit comparison against 2-3 state-of-the-art biosensors with citations and quantitative comparison. Third, manuscripts that lack engagement with Biosensors and Bioelectronics' recent issues are at risk of being told the contribution doesn't fit the publication conversation.